Ipamorelin
Growth Hormone Secretagogue | Selective GHRP
Overview
Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.
Key benefits
- Optimal GH stimulation with superior bioavailability
- Body composition improvements (lean mass, fat loss)
- Enhanced recovery and anti-aging effects
- Minimal side effects compared to other GHRPs
- No significant cortisol or prolactin elevation
- Improved sleep quality
Mechanism of action
Binds selectively to ghrelin receptors in pituitary gland, stimulating natural GH release with direct systemic delivery via injection, consistent GH pulse stimulation, no significant cortisol or prolactin elevation, and minimal hunger response.
Molecular data
- Type
- Growth hormone secretagogue
- Half-life
- ~2 hours
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Indications
What the research community uses this compound for, with self-reported effectiveness.
Growth Hormone
Body Composition
Recovery
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200mcg | 1x daily before bed | — |
| — | 250-300mcg | 2x daily (morning, pre-workout) | — |
| — | 200-250mcg | 2-3x daily | — |
| — | 200mcg | 1x daily 30min before bed | — |
| — | 200-250mcg | 1-2x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild hunger increase 20-30 minutes post-injection
- Slight drowsiness when taken before bed
- Water retention (mild)
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of cancer
- Severe kidney or liver disease
Monitoring
- Monitor for receptor desensitization after 3-4 months
- Cycle off periodically to maintain effectiveness
References
Primary literature and clinical-trial data informing this entry.